Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; www.thetcr.org) is an Open Access, peer-reviewed journal, published by AME Publishing Company, publishes the results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. TCR will publish laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving cancer patients lives. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles. The Official Publication of Society for Translational Cancer Research (STCR),Hong Kong
《癌症研究与治疗》是韩国癌症协会的一份同行评审的开放访问出版物。每季度出版一期,每年出版一册。简称为癌症治疗。它接受与实验和临床癌症研究相关的手稿。受试者包括致癌、肿瘤生物学、分子肿瘤学、癌症遗传学、肿瘤免疫学、流行病学、预测标志物和癌症预防、病理学、癌症诊断、筛查和治疗,包括化疗、手术、放射治疗、免疫治疗、基因治疗、多模态治疗和姑息治疗。 癌症研究与治疗(CRT)由SCI、MEDLine、PubMed、PubMed Central、Koreamed、CrossRef、Chemical Abstracts Service(CAS)、Scopus、Komci和Google Scholar编制索引/跟踪/覆盖。
期刊ISSN
|
1598-2998 |
最新的影响因子
|
4.6 |
最新CiteScore值
|
3.22 |
最新自引率
|
4.70% |
期刊官方网址
|
http://e-crt.org/ |
期刊投稿网址
|
http://journal.cancer.or.kr/submission/Login.html |
通讯地址
|
|
偏重的研究方向(学科)
|
ONCOLOGY- |
出版周期
|
|
平均审稿速度
|
>12周,或约稿 |
出版年份
|
0 |
出版国家/地区
|
SOUTH KOREA |
是否OA
|
No |
SCI期刊coverage
|
Science Citation Index Expanded(科学引文索引扩展) |
NCBI查询
|
PubMed Central (PMC)链接 全文检索(pubmed central) |
最新中科院JCR分区
|
大类(学科)
小类(学科)
JCR学科排名
医学
ONCOLOGY(肿瘤学) 2区
110/223
|
|||||||
最新的影响因子
|
4.6 | |||||||
最新公布的期刊年发文量 |
|
|||||||
总被引频次 | 2241 | |||||||
特征因子 | 0.005550 | |||||||
影响因子趋势图 |
2007年以来影响因子趋势图(整体平稳趋势)
|
最新CiteScore值
|
3.22
=
引文计数(2018)
文献(2015-2017)
=
1080次引用
335篇文献
|
||||||||||
文献总数(2014-2016) | 335 | ||||||||||
被引用比率
|
74% | ||||||||||
SJR
|
1.385 | ||||||||||
SNIP
|
1.474 | ||||||||||
CiteScore排名
|
|
||||||||||
CiteScore趋势图 |
CiteScore趋势图
|
||||||||||
scopus涵盖范围 |
scopus趋势图
|
本刊同领域相关期刊
|
|
期刊名称 | IF值 |
NEURO-ONCOLOGY | 15.9 |
JOURNAL OF NEURO-ONCOLOGY | 3.9 |
OncoImmunology | 7.2 |
JOURNAL OF IMMUNOTHERAPY | 3.9 |
Cancer Immunology Research | 10.1 |
Infectious Agents and Cancer | 3.7 |
CANCER IMMUNOLOGY IMMUNOTHERAPY | 5.8 |
INTEGRATIVE CANCER THERAPIES | 2.9 |
Hormones & Cancer | 3 |
本刊同分区等级的相关期刊
|
|
期刊名称 | IF值 |
JOURNAL OF NEURO-ONCOLOGY | 3.9 |
JOURNAL OF IMMUNOTHERAPY | 3.9 |
CANCER IMMUNOLOGY IMMUNOTHERAPY | 5.8 |
Molecular Therapy-Oncolytics | 5.7 |
American Journal of Translational Research | 2.2 |
Breast Care | 2.1 |
Breast Journal | 2.1 |
GYNECOLOGIC ONCOLOGY | 4.7 |
Journal of Gynecologic Oncology | 3.9 |
分享者 | 点评内容 |
发表日期:2018-07-31 |
研究方向:血液肿瘤
接收率: 中等(50%命中)
一本韩国杂志,投稿难度不算高,审稿速度挺快的。6月14投稿,一审大修一周修回,7月30二审小修,当天修回,第二天接收了。
(0)
|
发表日期:2016-08-24 |
研究方向:肿瘤基础
接收率: 非常困难(几乎不命中)
近三年影响影响因子:
2015年:4.245
2014年:3.318
2013年:2.975
韩国杂志,很少有国人文章发表,没有临床数据的文章基本秒拒,不会给任何理由。
(0)
|